Johnson & Johnson Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Deprecated 2012-01-31)
Johnson & Johnson (JNJ) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Deprecated 2012-01-31) of 6 Y for the 12-month period ending 2012-01-01, per its 10-K filed 2012-02-23.
Discontinued › Notes › Compensation Related Costs
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm · last filed 2012-02-23
- Johnson & Johnson share-based compensation arrangement by share-based payment award, fair value assumptions, expected term (deprecated 2012-01-31) for fiscal 2011 was 600.00%, a 0.00% change from fiscal 2010.
- Johnson & Johnson share-based compensation arrangement by share-based payment award, fair value assumptions, expected term (deprecated 2012-01-31) for fiscal 2010 was 600.00%, a 0.00% change from fiscal 2008.
- Johnson & Johnson share-based compensation arrangement by share-based payment award, fair value assumptions, expected term (deprecated 2012-01-31) for fiscal 2008 was 600.00%.
pure
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Deprecated 2012-01-31) 12 month |
|---|---|
| 2011-01-02 | 600.00% 10-K · filed 2011-02-25 |
| 2010-01-03 | 600.00% 10-K · filed 2011-02-25 |
| 2008-12-28 | 600.00% 10-K · filed 2011-02-25 |
Y
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Deprecated 2012-01-31) 12 month |
|---|---|
| 2012-01-01 | 6.00 Y 10-K · filed 2012-02-23 |
| 2011-01-02 | 6.00 Y 10-K · filed 2012-02-23 |
| 2010-01-03 | 6.00 Y 10-K · filed 2012-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |